Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections

被引:21
|
作者
Chalmers, James D. [1 ]
van Ingen, Jakko [2 ]
van der Laan, Roald [3 ]
Herrmann, Jean-Louis [4 ,5 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee, Scotland
[2] Radboud Univ Nijmegen, Radboudumc Ctr Infect Dis, Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands
[3] Insmed BV, Utrecht, Netherlands
[4] Univ Paris Saclay, UVSQ, Infect & Inflammat, INSERM, Montigny Le Bretonneux, France
[5] Grp Hosp Univ Paris Saclay, Hop Raymond Poincare, AP HP, Garches, France
来源
EUROPEAN RESPIRATORY REVIEW | 2021年 / 30卷 / 161期
关键词
PSEUDOMONAS-AERUGINOSA INFECTION; MECHANICALLY VENTILATED PATIENTS; TIME-KILL KINETICS; AVIUM COMPLEX; CYSTIC-FIBROSIS; CELL-WALL; AMIKACIN CONCENTRATIONS; ENCAPSULATED-AMIKACIN; RESISTANCE MECHANISMS; ABSCESSUS COMPLEX;
D O I
10.1183/16000617.0010-2021
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM pulmonary disease is difficult to treat because mycobacteria can evade host defences and antimicrobial therapy through extracellular persistence in biofilms and sequestration into macrophages. Management of NTM pulmonary disease remains challenging and outcomes are often poor, partly due to limited penetration of antibiotics into intracellular spaces and biofilms. Efficient drug delivery to the site of infection is therefore a key objective of treatment, but there is high variability in lung penetration by antibiotics. Inhalation is the most direct route of delivery and has demonstrated increased efficacy of antibiotics like amikacin compared with systemic administration. Liposomes are small, artificial, enclosed spherical vesicles, in which drug molecules can be encapsulated to provide controlled release, with potentially improved pharmacokinetics and reduced toxicity. They are especially useful for drugs where penetration of cell membranes is essential. Inhaled delivery of liposomal drug solutions can therefore facilitate direct access to macrophages in the lung where the infecting NTM may reside. A range of liposomal drugs are currently being evaluated in respiratory diseases.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Susceptibility to nontuberculous mycobacterial lung disease
    Sexton, P.
    Harrison, A. C.
    EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (06) : 1322 - 1333
  • [32] Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue
    Dartois, Veronique
    Dick, Thomas
    JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 219 (06):
  • [33] The clinical analysis of chronic obstructive pulmonary disease patients complicated with nontuberculous mycobacterial pulmonary disease
    孙宇新
    China Medical Abstracts(Internal Medicine), 2020, 37 (01) : 45 - 46
  • [34] Update on the Epidemiology of Pulmonary Nontuberculous Mycobacterial Infections Preface
    Kendall, Brian A.
    Winthrop, Kevin L.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 34 (01) : 87 - 94
  • [35] Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections
    Magis-Escurra, C.
    Alffenaar, J. W.
    Hoefnagels, I.
    Dekhuijzen, P. N. R.
    Boeree, M. J.
    van Ingen, J.
    Aarnoutse, R. E.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (03) : 256 - 261
  • [36] Incremental mortality associated with nontuberculous mycobacterial lung disease among US Medicare beneficiaries with chronic obstructive pulmonary disease
    Wang, Ping
    Marras, Theodore K.
    Hassan, Mariam
    Chatterjee, Anjan
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [37] Incremental Mortality Associated with Nontuberculous Mycobacterial Lung Disease Among US Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease
    Wang, P.
    Marras, T. K.
    Alemao, E.
    Hassan, M.
    Chatterjee, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [38] Incremental mortality associated with nontuberculous mycobacterial lung disease among US Medicare beneficiaries with chronic obstructive pulmonary disease
    Ping Wang
    Theodore K. Marras
    Mariam Hassan
    Anjan Chatterjee
    BMC Infectious Diseases, 23
  • [39] CHRONIC PULMONARY DISEASE DUE TO ATYPICAL MYCOBACTERIAL INFECTIONS
    LEWIS, AG
    DUNBAR, FP
    LASCHE, EM
    BOND, JO
    LERNER, EN
    WHARTON, DJ
    HARDY, AV
    DAVIES, R
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1959, 80 (02): : 188 - 199
  • [40] Surgical Treatment of Nontuberculous Mycobacterial Pulmonary Disease and a Combination of Nontuberculous Mycobacterium Pulmonary Disease and Pulmonary Tuberculosis
    Giller, Dmitry Borisivich
    Shcherbakova, Galina Vladimirovna
    Gerasimov, Andrey Nikolaevich
    Smerdin, Sergey Viktorovich
    Martel, Ivan Ivanovich
    Kesaev, Oleg Schamilevich
    Koroev, Vadim Valerievich
    Severova, Lyudmila Petrovna
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 120 : 12 - 21